EP
ELDN icon

Eversept Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Eversept Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-67,743
Closed -$154K – 67
2022
Q4 		$154K Hold
67,743
– – 0.01% 65
2022
Q3 		$187K Buy
67,743
+8,678
+15% +$27.6K 0.02% 68
2022
Q2 		$144K Sell
59,065
-54,943
-48% -$168K 0.01% 75
2022
Q1 		$449K Hold
114,008
– – 0.03% 79
2021
Q4 		$503K Hold
114,008
– – 0.03% 99
2021
Q3 		$705K Buy
+114,008
New +$797K 0.05% 97

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners's ELDN Position: Q1 2023 in Review

Eversept Partners sold out of Eledon Pharmaceuticals (ELDN) in Q1 2023, closing a stake of 67,743 shares — an estimated $154K sold.

Eversept Partners first reported a position in ELDN in Q3 2021 and held it in 6 quarters. The position peaked at $705K in Q3 2021. 30 funds tracked by Wall St. Rank hold ELDN as of Q1 2023.

  • Eversept Partners reported no remaining Eledon Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Eversept Partners sold 67,743 Eledon Pharmaceuticals shares in Q1 2023, an estimated $154K.
  • Eversept Partners first reported a position in Eledon Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Eversept Partners's Eledon Pharmaceuticals position peaked at $705K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2023.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.